Redeye: New ailments revealed in Doro

We had expected a recovery in Q3 and a sales growth of 10 percent but instead sales fell -2 percent. In North America, Doro has failed to introduce a 4G phone in time, meaning the weakness in US & Canada will continue into H2’18. Our EBIT estimates for 2018-2019 drop -40 percent and our base case falls with SEK 13 per share.

Read more in the Research Update by Viktor Westman at: https://goo.gl/jVvDVG 

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/

Prenumerera